DIAGNOS signs Memorandum of Understanding with Essilor International.
August 16 2021 - 9:00AM
Diagnos Inc. (“
DIAGNOS” or the
“
Company”) (TSX Venture: ADK) (OTCQB: DGNOF) (FRA:
4D4A), a leader in early detection of critical health issues, is
pleased to announce that it has entered into a Memorandum of
Understanding (MoU) with the Instruments division of Essilor
International, a subsidiary of EssilorLuxottica. Essilor
International is the world’s leading ophthalmic optics company.
Essilor designs, manufactures and markets a wide range of lenses
and diagnostic ophthalmic instruments.
The MoU is non-binding and forms the basis of a
potential distribution agreement with Essilor International for
DIAGNOS’ CARA platform for the AI-enhanced analysis of wide-field
retinal images, as well as of certain specified future developments
of the CARA platform for a variety of applications.
DIAGNOS has under development multiple new
applications involving AI-enhanced retinal imaging to address a
growing need for general purpose pathology identification. In
addition to localized retinal pathology, such as macular
degeneration and glaucoma, certain retinal pathologies are also
known indicators of various systemic disorders, including
cardiovascular and diabetic diseases. On July 20th 2021, DIAGNOS
announced a clinical trial with CommonSpirit Health Research
Institute in the USA for the early detection of stroke through the
inspection and analysis of the retina.
“DIAGNOS is focused on its commercialization
strategy and pursuing opportunities with potential partners. We are
very pleased that our AI-based technology has attracted the
attention of global eyecare sector leaders such as Essilor
International and we are looking forward to our discussions with
respect to a mutually beneficial potential worldwide distribution
agreement. At the same time, DIAGNOS continues to invest in
Research and Development, furthering the creation of our
intellectual property by partnering with Quebec government programs
and local university (École de Technologie Supérieure) to ensure
that we stay ahead of our competition worldwide,” said Mr.
André Larente, President of DIAGNOS.
About DIAGNOS:DIAGNOS is a
publicly traded Canadian corporation dedicated to early detection
of critical health problems based on its FLAIRE Artificial
Intelligence (AI) platform. FLAIRE allows for quick modifying and
developing of applications such as CARA (Computer Assisted Retina
Analysis). CARA’s image enhancement algorithms provide sharper,
clearer and easier-to-analyze retinal images. CARA is a
cost-effective tool for real-time screening of large volumes of
patients. CARA has been cleared for commercialization by the
following regulators: Health Canada, the FDA (USA), CE (Europe),
COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).
Additional information is available
at www.diagnos.com and www.sedar.com.
Information about Essilor International can be
found at www.essilor.com.
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
Corporate Communications:
Nancy Massicotte
IR Pro Communications Inc.
Dir: +1 604-507-3377
TF: 1-866-503-3377
Email: nancy@irprocommunications.com
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024